Sentinel lymph node biopsy for melanoma: indications and rationale.
BACKGROUND
The disease status of regional lymph nodes is the most important prognostic indicator for patients with melanoma. Sentinel lymph node biopsy (SLNB) was developed as a technique to surgically assess the regional lymph nodes and spare node-negative patients unnecessary and potentially morbid complete lymphadenectomies.


METHODS
We reviewed the literature on SLNB for cutaneous melanoma to provide insight into the rationale for the current widespread use of SLNB.


RESULTS
Multiple studies show that the status of the SLN is an important prognostic indicator. Those with positive SLNs have significantly decreased disease-free and melanoma-specific survival compared with those who have negative SLNs. In the Multicenter Selective Lymphadenectomy Trial I (MSLT-I), in which patients with intermediate-thickness melanoma were randomized to SLNB (and immediate completion lymphadenectomy if the SLN was positive) vs observation (and a lymphadenectomy only after presenting with clinically evident recurrence), the 5-year survival rate was 72.3% for patients with positive sentinel nodes and 90.2% for those with negative sentinel nodes (P < .001). Although overall survival was not increased in patients who underwent SLNB compared with those who were randomized to observation, patients who underwent SLNB had a significantly increased 5-year disease-free survival rate compared with those who underwent observation alone (78.3% in the biopsy group and 73.1% in the observation group; P = .009). For those with nodal metastases, patients who underwent SLNB and immediate lymphadenectomy had an increased overall 5-year survival rate compared with those who had lymphadenectomy only after presenting with clinically evident disease (72.3% vs 52.4%; P = .004). Moreover, other studies show that for patients with thin melanomas <or= 1.0 mm, the overall survival rate is significantly worse for those with positive SLNs compared to those with negative SLNs. For thin melanomas, Breslow depth >or= 0.76 mm and increased mitotic rate have been shown to be associated with an increased incidence of SLN metastases.


CONCLUSIONS
SLNB provides important prognostic and staging data with minimal morbidity and can be used to identify regional node-negative patients who would not benefit from a complete nodal dissection. In our opinion, SLNB should be performed on most patients (with acceptable surgical and anesthesia risk) who have melanomas with a Breslow depth >or= 0.76 mm.
Phan
Giao Q
GQ
Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, USA.
Messina
Jane L
JL
Sondak
Vernon K
VK
Zager
Jonathan S
JS
D018572:Disease-Free Survival; D006801:Humans; D008545:Melanoma / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy / Q000379:methods* / Q000639:trends; D012878:Skin Neoplasms / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate